Opus Genetics stockholders approve doubling authorized shares to 250M at annual meeting

Opus Genetics, Inc.

Stock increase proposal passed: 45,360,642 for, 1,486,247 against, 429,479 abstentions.
Say-on-pay approved with 34,862,743 votes for, 259,749 against, 110,779 abstentions.
All nine board nominees elected, each receiving over 33.8M votes for.
Ernst & Young ratified as independent auditor for FY 2026.
Meeting held April 20, 2026; all proposals passed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.